Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary

Inozyme Pharma

09/05/2023 15:12

* Inozyme Pharma Inc  INZY.OQ  reported a quarterly adjusted
loss
of 40 cents​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss
of 45 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inozyme Pharma Inc's reported EPS for the quarter was a
loss
of 40 cents​.
    * The mean earnings estimate of analysts had fallen by
about 10.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Inozyme Pharma Inc shares had risen by 4.4% this
quarter and
gained 469.5% so far this year.
    * The company reported a quarterly loss of $17.4 million.
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 02:12 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.45          -0.40          Beat
 Dec. 31 2022      -0.45          -0.42          Beat
 Sep. 30 2022      -0.43          -0.38          Beat
 Jun. 30 2022      -0.48          -0.38          Beat